Author Archive: Jeremy Parkinson

E
                                                
                        ADRs Best & Worst Report – Monday, April 17

E ADRs Best & Worst Report – Monday, April 17

The best sector in ADRs is utilities. The top countries are Mexico, Chile, and Switzerland. The average score across our ADR universe is 52.61. For perspective, the score averages 53.52 and 53.80 over the past four and eight weeks. The average ADR in our universe slipped 0.48% in the past week, and is trading -14.53% […]
Gold ETFs Do Not Always Do The Same

Gold ETFs Do Not Always Do The Same

Generally, gold ETFs should behave in the same way. For example, when one gold ETF accumulates gold, the other ETFs should do the same. However, sometimes it is not the case. Look at these two charts: source: Simple Digressions Note that in January the first gold ETF, IAU, accumulated 125.2 thousand ounces of gold (its […]
The Economy Is Like A Circus

The Economy Is Like A Circus

The economy is like a circus. It comes to town, and eventually it leaves town. We get paid in tickets to this circus. As long as the circus stays in town, we can use our tickets. Once the circus leaves town, we are pretty much out of luck. The reason the circus stays in town […]
Let’s Stick To What We Know

Let’s Stick To What We Know

Investors have found it difficult to resist the temptation to become armchair generals in response to the recent flurry of geopolitical volatility. I have some sympathy for that. Political experts told us that Mr. Trump would mark the beginning of a new U.S. isolationism, and even speculated about the emergence of a new Monroe doctrine. […]
Too Hot To Handle Twist: Econoday “Thankful” For Empire State Manufacturing Cooling

Too Hot To Handle Twist: Econoday “Thankful” For Empire State Manufacturing Cooling

The Econoday consensus estimate for the Empire State manufacturing index was +15.0 in a range of 13.0 to 17.2. The actual index reading was 5.2, down 11.2 points from last month’s reading of 16.4. In a new twist on the state of the allegedly strengthening economy, Econoday is “thankful” for the cooling. Highlights Activity is thankfully cooling in […]
Does Market Sentiment Help Explain Momentum?

Does Market Sentiment Help Explain Momentum?

Momentum is the tendency for assets that have performed well (poorly) in the recent past to continue to perform well (poorly) in the future, at least for a short period of time. In 1997, Mark Carhart, in his study “On Persistence in Mutual Fund Performance,” was the first academic to use momentum, together with the […]
Global Infrastructure ETF (IGF) Hits New 52-Week High

Global Infrastructure ETF (IGF) Hits New 52-Week High

For investors looking for momentum, the iShares Global Infrastructure ETF (IGF –Free Report) is probably on your radar now. The fund just hit a 52-week high and shares of IGF are up roughly 14.41% from their 52-week low price of $37.33/share. But could more gains be ahead for this ETF? Let’s take a quick look at […]
Ford: Time To Buy It

Ford: Time To Buy It

FIBOCALL: Ford (F) – mentioned on CNBC The whole panel on CNBC did not like F here, so it’s a good reason to own some. With the 11/9/16 low @ 11.07 holding, you can own some now. A close above 11.25 to add to longs. The 20 DMA @ 11.49 50 DMA @ 12.13 Our […]
Alibaba Group Holding Ltd. Affiliate Ups Offer For MoneyGram International Inc.

Alibaba Group Holding Ltd. Affiliate Ups Offer For MoneyGram International Inc.

Written by StockNews.com China-based Ant Financial, an online payments specialist founded by Alibaba Group Holding Ltd. (NYSE:BABA), has substantially upped its takeover offer to U.S.-based money transfer giant MoneyGram International Inc. (NASDAQ:MGI). Ant boosted its bid for MoneyGram by 36% from its prior offer, to $18 per share in cash, or $1.2 billion. That’s up from […]
Incyte, Eli Lilly Plunge After FDA Won’t Approve Arthritis Drug

Incyte, Eli Lilly Plunge After FDA Won’t Approve Arthritis Drug

Shares of drugmaker Incyte (INCY) and mega-cap partner Eli Lilly (LLY) are sliding after the Food and Drug Administration rejected their application for rheumatoid arthritis therapy baricitinib in its current form, due to safety concerns. Nonetheless, the latter reaffirmed its 2017 and mid-term guidance. The news sparked varied reactions from Wall Street analysts. While some […]